A multi-tiered hierarchical Bayesian approach to derive toxic equivalency factors for dioxin-like compounds
Regul Toxicol Pharmacol. 2023 Jul 27;143:105464. doi: 10.1016/j.yrtph.2023.105464. Online ahead of print.ABSTRACTIn 2005, the World Health Organization (WHO) re-evaluated Toxic Equivalency factors (TEFs) developed for dioxin-like compounds believed to act through the Ah receptor based on an updated database of relative estimated potency (REP)(REP2004 database). This re-evalution identified the need to develop a consistent approach for dose-response modeling. Further, the WHO Panel discussed the significant heterogeneity of experimental datasets and dataset quality underlying the REPs in the database. There is a critical ne...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Caroline Ring Alexander Blanchette William D Klaren Seneca Fitch Laurie Haws Matthew W Wheeler Michael DeVito Nigel Walker Daniele Wikoff Source Type: research

Anticancer effect of terpenes: focus on malignant melanoma
Pharmacol Rep. 2023 Jul 29. doi: 10.1007/s43440-023-00512-1. Online ahead of print.ABSTRACTMelanoma is a highly aggressive and life-threatening form of skin cancer that accounts for a significant proportion of cancer-related deaths worldwide. Although conventional cancer therapies, such as surgical excision, chemotherapy, and radiation, have been used to treat malignant melanoma, their efficacy is often limited due to the development of resistance and adverse side effects. Therefore, there is a growing interest in developing alternative treatment options for melanoma that are more effective and less toxic. Terpenes, a dive...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Paula Wr óblewska-Łuczka Justyna Cabaj Julia Bargie ł Jarogniew J Łuszczki Source Type: research

A multi-tiered hierarchical Bayesian approach to derive toxic equivalency factors for dioxin-like compounds
Regul Toxicol Pharmacol. 2023 Jul 27:105464. doi: 10.1016/j.yrtph.2023.105464. Online ahead of print.ABSTRACTIn 2005, the World Health Organization (WHO) re-evaluated Toxic Equivalency factors (TEFs) developed for dioxin-like compounds believed to act through the Ah receptor based on an updated database of relative estimated potency (REP)(REP2004 database). This re-evalution identified the need to develop a consistent approach for dose-response modeling. Further, the WHO Panel discussed the significant heterogeneity of experimental datasets and dataset quality underlying the REPs in the database. There is a critical need t...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Caroline Ring Alexander Blanchette William D Klaren Seneca Fitch Laurie Haws Matthew W Wheeler Michael DeVito Nigel Walker Daniele Wikoff Source Type: research

Anticancer effect of terpenes: focus on malignant melanoma
Pharmacol Rep. 2023 Jul 29. doi: 10.1007/s43440-023-00512-1. Online ahead of print.ABSTRACTMelanoma is a highly aggressive and life-threatening form of skin cancer that accounts for a significant proportion of cancer-related deaths worldwide. Although conventional cancer therapies, such as surgical excision, chemotherapy, and radiation, have been used to treat malignant melanoma, their efficacy is often limited due to the development of resistance and adverse side effects. Therefore, there is a growing interest in developing alternative treatment options for melanoma that are more effective and less toxic. Terpenes, a dive...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Paula Wr óblewska-Łuczka Justyna Cabaj Julia Bargie ł Jarogniew J Łuszczki Source Type: research

A multi-tiered hierarchical Bayesian approach to derive toxic equivalency factors for dioxin-like compounds
Regul Toxicol Pharmacol. 2023 Jul 27:105464. doi: 10.1016/j.yrtph.2023.105464. Online ahead of print.ABSTRACTIn 2005, the World Health Organization (WHO) re-evaluated Toxic Equivalency factors (TEFs) developed for dioxin-like compounds believed to act through the Ah receptor based on an updated database of relative estimated potency (REP)(REP2004 database). This re-evalution identified the need to develop a consistent approach for dose-response modeling. Further, the WHO Panel discussed the significant heterogeneity of experimental datasets and dataset quality underlying the REPs in the database. There is a critical need t...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Caroline Ring Alexander Blanchette William D Klaren Seneca Fitch Laurie Haws Matthew W Wheeler Michael DeVito Nigel Walker Daniele Wikoff Source Type: research

Anticancer effect of terpenes: focus on malignant melanoma
Pharmacol Rep. 2023 Jul 29. doi: 10.1007/s43440-023-00512-1. Online ahead of print.ABSTRACTMelanoma is a highly aggressive and life-threatening form of skin cancer that accounts for a significant proportion of cancer-related deaths worldwide. Although conventional cancer therapies, such as surgical excision, chemotherapy, and radiation, have been used to treat malignant melanoma, their efficacy is often limited due to the development of resistance and adverse side effects. Therefore, there is a growing interest in developing alternative treatment options for melanoma that are more effective and less toxic. Terpenes, a dive...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Paula Wr óblewska-Łuczka Justyna Cabaj Julia Bargie ł Jarogniew J Łuszczki Source Type: research

A multi-tiered hierarchical Bayesian approach to derive toxic equivalency factors for dioxin-like compounds
Regul Toxicol Pharmacol. 2023 Jul 27:105464. doi: 10.1016/j.yrtph.2023.105464. Online ahead of print.ABSTRACTIn 2005, the World Health Organization (WHO) re-evaluated Toxic Equivalency factors (TEFs) developed for dioxin-like compounds believed to act through the Ah receptor based on an updated database of relative estimated potency (REP)(REP2004 database). This re-evalution identified the need to develop a consistent approach for dose-response modeling. Further, the WHO Panel discussed the significant heterogeneity of experimental datasets and dataset quality underlying the REPs in the database. There is a critical need t...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Caroline Ring Alexander Blanchette William D Klaren Seneca Fitch Laurie Haws Matthew W Wheeler Michael DeVito Nigel Walker Daniele Wikoff Source Type: research

Anticancer effect of terpenes: focus on malignant melanoma
Pharmacol Rep. 2023 Jul 29. doi: 10.1007/s43440-023-00512-1. Online ahead of print.ABSTRACTMelanoma is a highly aggressive and life-threatening form of skin cancer that accounts for a significant proportion of cancer-related deaths worldwide. Although conventional cancer therapies, such as surgical excision, chemotherapy, and radiation, have been used to treat malignant melanoma, their efficacy is often limited due to the development of resistance and adverse side effects. Therefore, there is a growing interest in developing alternative treatment options for melanoma that are more effective and less toxic. Terpenes, a dive...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Paula Wr óblewska-Łuczka Justyna Cabaj Julia Bargie ł Jarogniew J Łuszczki Source Type: research

A multi-tiered hierarchical Bayesian approach to derive toxic equivalency factors for dioxin-like compounds
Regul Toxicol Pharmacol. 2023 Jul 27:105464. doi: 10.1016/j.yrtph.2023.105464. Online ahead of print.ABSTRACTIn 2005, the World Health Organization (WHO) re-evaluated Toxic Equivalency factors (TEFs) developed for dioxin-like compounds believed to act through the Ah receptor based on an updated database of relative estimated potency (REP)(REP2004 database). This re-evalution identified the need to develop a consistent approach for dose-response modeling. Further, the WHO Panel discussed the significant heterogeneity of experimental datasets and dataset quality underlying the REPs in the database. There is a critical need t...
Source: Pharmacological Reports - July 29, 2023 Category: Drugs & Pharmacology Authors: Caroline Ring Alexander Blanchette William D Klaren Seneca Fitch Laurie Haws Matthew W Wheeler Michael DeVito Nigel Walker Daniele Wikoff Source Type: research

Retraction Note: Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular A β1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway
Pharmacol Rep. 2023 Jul 21. doi: 10.1007/s43440-023-00511-2. Online ahead of print.NO ABSTRACTPMID:37477845 | DOI:10.1007/s43440-023-00511-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - July 21, 2023 Category: Drugs & Pharmacology Authors: Noorul Hasan Saima Zameer Abul Kalam Najmi Suhel Parvez Mohammad Shahar Yar Mohd Akhtar Source Type: research

Retraction Note: Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular A β1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway
Pharmacol Rep. 2023 Jul 21. doi: 10.1007/s43440-023-00511-2. Online ahead of print.NO ABSTRACTPMID:37477845 | DOI:10.1007/s43440-023-00511-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - July 21, 2023 Category: Drugs & Pharmacology Authors: Noorul Hasan Saima Zameer Abul Kalam Najmi Suhel Parvez Mohammad Shahar Yar Mohd Akhtar Source Type: research

Retraction Note: Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular A β1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway
Pharmacol Rep. 2023 Jul 21. doi: 10.1007/s43440-023-00511-2. Online ahead of print.NO ABSTRACTPMID:37477845 | DOI:10.1007/s43440-023-00511-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - July 21, 2023 Category: Drugs & Pharmacology Authors: Noorul Hasan Saima Zameer Abul Kalam Najmi Suhel Parvez Mohammad Shahar Yar Mohd Akhtar Source Type: research

Retraction Note: Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular A β1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway
Pharmacol Rep. 2023 Jul 21. doi: 10.1007/s43440-023-00511-2. Online ahead of print.NO ABSTRACTPMID:37477845 | DOI:10.1007/s43440-023-00511-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - July 21, 2023 Category: Drugs & Pharmacology Authors: Noorul Hasan Saima Zameer Abul Kalam Najmi Suhel Parvez Mohammad Shahar Yar Mohd Akhtar Source Type: research

Retraction Note: Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular A β1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway
Pharmacol Rep. 2023 Jul 21. doi: 10.1007/s43440-023-00511-2. Online ahead of print.NO ABSTRACTPMID:37477845 | DOI:10.1007/s43440-023-00511-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - July 21, 2023 Category: Drugs & Pharmacology Authors: Noorul Hasan Saima Zameer Abul Kalam Najmi Suhel Parvez Mohammad Shahar Yar Mohd Akhtar Source Type: research

Retraction Note: Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular A β1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway
Pharmacol Rep. 2023 Jul 21. doi: 10.1007/s43440-023-00511-2. Online ahead of print.NO ABSTRACTPMID:37477845 | DOI:10.1007/s43440-023-00511-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - July 21, 2023 Category: Drugs & Pharmacology Authors: Noorul Hasan Saima Zameer Abul Kalam Najmi Suhel Parvez Mohammad Shahar Yar Mohd Akhtar Source Type: research